Thomas J Lynch, MD Massachusetts General Hospital Chief, Hematology Oncology Director, Center for Thoracic Cancers Professor of Medicine, Harvard Medical School Boston, Massachusetts
	Click here to download entire interview
Track 1	FLEX trial: Cetuximab with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of advanced, EGFR-positive non-small cell lung cancer (NSCLC)
Track 2	North American study results of carboplatin/paclitaxel with or without cetuximab as first-line therapy for advanced NSCLC
Track 3	Clinical implications of the FLEX trial
Track 4	Proposed randomized trial of carboplatin/paclitaxel/bevacizumab with or without cetuximab in bevacizumab-eligible patients
Track 5	Perspective on the cost effectiveness of cetuximab in advanced NSCLC
Track 6	Contraindications to bevacizumab in NSCLC
Track 7	Continuation of bevacizumab upon disease progression
Track 8	EGFR mutation and response to erlotinib or gefitinib
Track 9	C-MET oncogene and T790M mutations predict resistance to EGFR tyrosine kinase inhibitors (TKIs)
Track 10	IGF signaling and acquired resistance to EGFR TKIs
Track 11	Increasing number of biomarkers to guide decision-making in lung cancer treatment
Track 12	Ongoing clinical trials in lung cancer evaluating the multikinase inhibitor vandetanib (ZD6474)
Track 13	Sorafenib or sunitinib as later-line therapy for advanced NSCLC
Track 14	Pemetrexed as maintenance or first-line therapy
Track 15	Detection of EGFR mutations in circulating lung cancer cells
Track 16	Cisplatin/docetaxel as adjuvant chemotherapy for patients with NSCLC
Track 17	Adjuvant therapy for patients with EGFR mutations
Track 18	Management of EGFR inhibitor-associated cutaneous toxicities
Track 19	Future directions in the treatment of NSCLC

F Anthony Greco, MD Director, Sarah Cannon Cancer Center Nashville, Tennessee
	Click here to download entire interview
Track 1	Perspective on the FLEX trial results
Track 2	Negative predictive role of K-ras mutation in colon cancer
Track 3	Off-protocol use of cetuximab for patients with lung cancer
Track 4	Cetuximab-induced anaphylaxis
Track 5	Incidence and clinical management of cetuximab-associated rash
Track 6	Use of first-line erlotinib for patients with advanced NSCLC and EGFR mutations
Track 7	Off-protocol adjuvant chemotherapy with erlotinib for patients with EGFR mutations
Track 8	Use of cetuximab for patients with metastatic NSCLC with and without contraindications to bevacizumab
Track 9	Bevacizumab-associated adverse events in selected patients with NSCLC
Track 10	Evaluation of bevacizumab in the adjuvant setting across multiple tumor types
Track 11	Investigation of the multikinase inhibitor vandetanib in NSCLC
Track 12	Role of pemetrexed in the treatment of Stage IIIB/IV nonsquamous NSCLC
Track 13	Potential patient benefits from nanoparticle albumin-bound (nab) paclitaxel in NSCLC
Track 14	Pathologic evaluation of cancer of unknown primary (CUP)
Track 15	Molecular profiling of patients with CUP
Track 16	Currently available laboratory tests for CUP
Track 17	Case discussion: A 55-year-old woman with multiple liver metastases and no apparent primary tumor
Track 18	Case discussion: A 62-year-old former smoker with a mediastinal mass whose tumor was TTF-1-positive
Track 19	Paclitaxel/carboplatin with bevacizumab/erlotinib as first-line treatment for CUP
Track 20	Underestimation of the incidence of CUP in the United States

Rogerio C Lilenbaum, MD Clinical Associate Professor of Medicine University of Miami School of Medicine Director, Thoracic Oncology Program The Mount Sinai Comprehensive Cancer Center Miami Beach, Florida
	Click here to download entire interview
Track 1	Role of EGFR and K-ras assessment in NSCLC
Track 2	Rash associated with EGFR TKIs and monoclonal antibodies
Track 3	Indirect comparison of chemotherapy with cetuximab to chemotherapy with bevacizumab for advanced NSCLC
Track 4	AVAiL: Bevacizumab with cisplatin/gemcitabine for chemotherapy-naïve patients with advanced or recurrent nonsquamous NSCLC
Track 5	Unraveling the contraindications to bevacizumab in NSCLC
Track 6	Proposed SWOG trial evaluating bevacizumab with cetuximab in NSCLC
Track 7	Selection of cisplatin-based chemotherapy in the adjuvant setting
Track 8	Role of maintenance therapy in the treatment of advanced NSCLC
Track 9	Use of maintenance bevacizumab and pemetrexed
Track 10	Benefits of pemetrexed predicted by nonsquamous cell histology
Track 11	CALGB-30605: Induction carboplatin/nab paclitaxel followed by thoracic radiation therapy and erlotinib for poor-risk, Stage III NSCLC
Track 12	Clinical trials incorporating biologics into chemoradiation therapy for locally advanced NSCLC

Robert Pirker, MD Professor of Medicine Department of Medicine I Medical University of Vienna Vienna, Austria
	Click here to download entire interview
Track 1	Background and eligibility of the FLEX study
Track 2	FLEX: Efficacy results
Track 3	FLEX: Ethnicity subgroup analyses
Track 4	FLEX: Side effects and tolerability
Track 5	Prophylaxis for cetuximab-associated rash with topical ointments
Track 6	Incorporating cetuximab in combination with chemotherapy into the clinical setting
Track 7	Reaction to Dr Lynch’s ASCO discussion of the FLEX trial results
Track 8	Rate of febrile neutropenia in the FLEX trial
Track 9	Predictive factors for EGFR TKIs and monoclonal antibodies in NSCLC
Track 10	Ongoing clinical trials evaluating chemotherapy with biologic combinations in advanced NSCLC
Track 11	Impact of rash associated with EGFR TKIs and monoclonal antibodies on patient compliance in adjuvant clinical trials